Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant CHO Cell COVID-19 Vaccine in Children 3-17 Years
NCT04961359Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZF2001 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Zhifei Biological. Primary endpoint: Incidence of adverse events. Started Jul 2021; status: completed.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04961359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961359.